Join us for an in-depth exploration of the most impactful developments presented at the EULAR 2025 Congress, focusing specifically on Systemic Lupus Erythematosus and Lupus Nephritis.

We break down the key takeaways, including:

- New insights into hydroxychloroquine monitoring and glucocorticoid tapering guidance

- "LAMDA," a novel scoring system for lupus arthritis

- Breakthroughs in LN treatment, including the REGENCY trial for obinutuzumab and combinations with existing therapies.

- Updated perspectives on belimumab and anifrolumab, exciting novel therapies in development, and the future of cellular therapies for severe lupus.

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.